...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells.
【24h】

Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells.

机译:环氧合酶抑制剂的细胞抑制作用和细胞毒性作用以及它们与二十二碳六烯酸的协同作用对人皮肤黑色素瘤A-375细胞的生长。

获取原文
获取原文并翻译 | 示例

摘要

Recent studies have suggested the inhibition of cyclooxygenase-2 (COX-2) as strategy to prevent colorectal cancer. In this study, the cytostatic and cytotoxic effects of different non-steroidal anti-inflammatory drugs (NSAIDs), all of them are reported COX inhibitors, were investigated in human skin melanoma A-375 cells. Using BrdU-cell proliferation assay, we showed that 50 and 100 microM of celecoxib (CEL) reduced proliferation of the melanoma cells at 72-h incubations by 34.0% and 82.7%, respectively. As determined by Toxilight-cytotoxicity assay, the drug was only toxic to the cancer cells at 100 microM. Indomethacin (IND) also inhibited the cell proliferation by about 40% at 240 and 480 pM and was only slightly toxic to the melanoma. Neither aspirin (ASP) nor piroxicam (PIR) exhibited cytostatic or cytotoxic effect on the cancer cells. Combinatory effects of the above NSAIDs with dietary docosahexaenoic acid (DHA) on inhibiting growth of the melanoma cells were further elucidated. Each of the NSAIDs, at doses 10-480 pM, was incubated simultaneously with the melanoma cells and 160 pM of DHA for 72 h. Results from MTT assay showed that both CEL and IND, starting from 20 microM. exhibited additive effects on the DHA-induced growth inhibition. ASP also enhanced the DHA-induced growth inhibition by 42.8% at 480 microM. To our surprise, although PRX did not suppress the melanoma growth, the drug at 40-240 microM enhanced the DHA-induced growth inhibition by 15.9-66.4%, respectively. Results from these studies suggest that the anticancer effects of NSAIDs may not be explained solely by their COX-inhibitory activities. Further studies are therefore required to understand their modes of action, before they could be used alone or in combinations with other agents for cancer chemoprevention.
机译:最近的研究表明抑制环氧合酶2(COX-2)作为预防结直肠癌的策略。在这项研究中,在人皮肤黑色素瘤A-375细胞中研究了不同的非甾体类抗炎药(NSAID)的细胞抑制作用和细胞毒性作用,所有这些药物均被报道为COX抑制剂。使用BrdU细胞增殖测定法,我们发现50和100 microM的塞来昔布(CEL)在72小时的孵育中分别降低了黑色素瘤细胞的增殖34.0%和82.7%。如通过Toxilight-细胞毒性测定所确定的,该药物仅对癌细胞具有100 microM的毒性。消炎痛(IND)在240和480 pM时也能抑制细胞增殖约40%,对黑素瘤的毒性很小。阿司匹林(ASP)和吡罗昔康(PIR)均未显示出对癌细胞具有细胞抑制或细胞毒性作用。进一步阐明了上述NSAID与膳食二十二碳六烯酸(DHA)在抑制黑素瘤细胞生长方面的联合作用。将每种NSAID(剂量为10-480 pM)与黑素瘤细胞和160 pM DHA同时孵育72小时。 MTT分析的结果显示CEL和IND均从20 microM开始。对DHA诱导的生长抑制表现出累加效应。 ASP还在480 microM时将DHA诱导的生长抑制作用提高了42.8%。令我们惊讶的是,尽管PRX不能抑制黑素瘤的生长,但40-240 microM的药物分别使DHA诱导的生长抑制提高了15.9-66.4%。这些研究的结果表明,NSAIDs的抗癌作用可能不能仅通过其COX抑制活性来解释。因此,在将它们单独或与其他化学预防药物结合使用之前,需要进一步研究以了解其作用方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号